Scholarlink

Purpose <p>Real-world data (RWD) has become essential to guide oncology practice and policy. However, in Morocco, the extent and quality of available oncology RWD remain unclear. This study aims to address this gap by examining the current status of RWD in oncology in the Moroccan context.</p> Methods <p>We systematically identified and synthesized 308 Moroccan cancer studies (1985–2025) drawn from different electronic databases. Eligible studies included those based on population registries, as well as retrospective and prospective clinical cohorts, molecular and genetic studies, and psycho-oncological or health-system analyses. Data were extracted across five domains: (1) epidemiology, (2) molecular biology, (3) treatment outcomes, (4) survivorship and quality of life, and (5) system-level and public health interventions.</p> Results <p>Breast (25%), colorectal (12%), and lung cancers (10%) were the most frequently studied. Most RWD outputs originated from Casablanca (34%), followed by Rabat (27%) and Fez (18%). Clinical and epidemiological studies (56%) were the most predominant study types while molecular papers (21%) highlighted actionable biomarkers: EGFR, KRAS, TP53, BRCA1/2, and VEGF.56</p> Conclusion <p>Morocco has transitioned from case-series oncology research to integrated molecular-epidemiologic RWD networks. Strengthening national data interoperability, biobank integration, and linkage between registries and clinical outcomes is now imperative.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world data on oncology in Morocco: a narrative review of four decades of national evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Sihame Lkhoyaali,
  • Chaymaa Ghizlane,
  • Badiaa Batlamous,
  • Emmelda N. C. Efountame Nkoghe,
  • Ibrahim El Ghissassi,
  • Hind Mrabti,
  • Hassan Errihani,
  • Mohamed Khalis,
  • Saber Boutayeb

摘要

Purpose

Real-world data (RWD) has become essential to guide oncology practice and policy. However, in Morocco, the extent and quality of available oncology RWD remain unclear. This study aims to address this gap by examining the current status of RWD in oncology in the Moroccan context.

Methods

We systematically identified and synthesized 308 Moroccan cancer studies (1985–2025) drawn from different electronic databases. Eligible studies included those based on population registries, as well as retrospective and prospective clinical cohorts, molecular and genetic studies, and psycho-oncological or health-system analyses. Data were extracted across five domains: (1) epidemiology, (2) molecular biology, (3) treatment outcomes, (4) survivorship and quality of life, and (5) system-level and public health interventions.

Results

Breast (25%), colorectal (12%), and lung cancers (10%) were the most frequently studied. Most RWD outputs originated from Casablanca (34%), followed by Rabat (27%) and Fez (18%). Clinical and epidemiological studies (56%) were the most predominant study types while molecular papers (21%) highlighted actionable biomarkers: EGFR, KRAS, TP53, BRCA1/2, and VEGF.56

Conclusion

Morocco has transitioned from case-series oncology research to integrated molecular-epidemiologic RWD networks. Strengthening national data interoperability, biobank integration, and linkage between registries and clinical outcomes is now imperative.